Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC)

Tien Hoang,KyungMann Kim,Joseph Merchant,Anne M. Traynor,Harish G. Ahuja,Gregory A. Masters,James McGovern,Kurt R. Oettel,F.A. Sánchez,Joan H. Schiller

Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC)

2004

Tien Hoang
KyungMann Kim
Joseph Merchant
Anne M. Traynor
Harish G. Ahuja
Gregory A. Masters
James McGovern
Kurt R. Oettel
F.A. Sánchez
Joan H. Schiller

7103 Background: Exisulind is an oral selective apoptotic antineoplastic drug which inhibits the cyclic GMP phosphodiesterase. The combination of exisulind and gemcitabine produced an additive anti...

Keywords:

Exisulind
non-small cell lung cancer (NSCLC)
Pathology
Gemcitabine
Oncology
Cancer research
Internal medicine
Medicine
phase i ii
in patient
Apoptosis
antineoplastic drug
cyclic gmp phosphodiesterase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations